with previous findings which demonstrated the absolute need to decrease the tumor burden to have successful vaccination strategies and to reach durative disease free survival rates or cures today high dose and or poly chemotherapeutic approaches are commonly used however these approaches are associated with serious constrains including high toxicity and increased risk of secondary drug induced neoplasms these undesired side effects are of particular relevance in young patients thus alternative protocols taking advantage of more specific compounds kinase inhibitors less toxic regiments i e chemoprevention protocols tailored schedules etc capable to better preserve the host immunity or chemotherapeutic compounds favoring necrosis versus apoptosis which should enhance tumor antigen presentation should be consider in association with the vaccine protocols our data support this avenue and provide the scientific rational for future clinical applications the protocols of alk dna vaccination used in the present mouse model will be adapted for clinical application in human patients alk dna vaccination protocols will be designed following the guidelines established for other antigens in human patients such as in prostate cancer miller et a m et al j immunother 28 389 95 2005 roos a k et al methods mol biol 423 463 72 2008 as a starting protocol three different amounts of alk dna are used 100 u03bcg 90 u03bcg intramuscularly im 10 u03bcg intradermally id 300 u03bcg 270 u03bcg im 30 u03bcg id and 900 u03bcg 810 u03bcg im 90 u03bcg id to optimize vaccination the following cytokines will be.